Company profile
NEURALINK
Implantable brain-computer interfaces designed to restore autonomy for people with severe neurological impairments.
Private; venture-backed clinical-stage medical device companyFremont, California, United States
Company links
Company links
Neuralink
https://neuralink.com/01 - Company overview
Neuralink at a glance.
StagePrivate; venture-backed clinical-stage medical device company
SectorBrain-computer interface, Neurotechnology, Medical devices, Robotics, Assistive technology, Clinical trials
LocationFremont, California, United States
02 - The story
Implantable brain-computer interfaces designed to restore autonomy for people with severe neurological impairments.
Neuralink develops implantable brain-computer interface technology that records neural activity and translates intended movement or communication signals into control of external devices. The company’s PRIME study evaluates its N1 Implant, R1 Robot, and N1 User App in participants with paralysis, while its broader roadmap includes assistive applications for computer control, robotic arms, speech restoration, and vision-related research. Neuralink is privately held and venture-backed; its devices remain investigational and are not commercially available or FDA approved.
04 - Traction
What is working.
Signal 01Official LinkedIn profile lists Neuralink as privately held, founded in 2016, headquartered in Fremont, California, and focused on ultra-high-bandwidth brain-machine interfaces.
Signal 02The PRIME Study brochure describes Neuralink’s first brain-computer interface clinical trial evaluating the N1 Implant, R1 Robot, and N1 User App for enabling people with paralysis to control external devices.
Signal 03Neuralink’s PRIME Study is registered on ClinicalTrials.gov as a first-in-human early feasibility study sponsored by Neuralink Corp.
Signal 04Neuralink announced a $650 million Series E financing in June 2025; TechCrunch reported participation from investors including ARK Invest, Founders Fund, Sequoia Capital, and Thrive Capital.
Signal 05A recent official LinkedIn update reported 21 participants enrolled in Neuralink trials worldwide.